Table 4. Treatment and outcomes of MIS-C with or without hyperferritinemia

	MIS-C with hyperferritinemia (n = 11)	MIS-C without hyperferritinemia (n = 11)	P value
Initial IVIG	11 (100.0)	8 (72.7)	0.214
Initial treatment failure (IVIG resistance)	5 (45.5)	2 (18.2)	0.361
Second or third IVIG	3 (27.3)	1 (9.1)	0.586
Second or third IVMP	5 (45.5)	2 (18.2)	0.361
Biologics (anakinra)	1 (9.1)	0 (0.0)	1.000
Two or more immunomodulators1)	11 (100.0)	6 (54.5)	0.035
Empirical antibiotics	11 (100.0)	8 (72.7)	0.214
Vasoactive drugs	5 (45.5)	0 (0.0)	0.035
ICU admission	5 (45.5)	0 (0.0)	0.035
Coronary complications	2 (18.2)	3 (27.3)	1.000
Mortality	0 (0.0)	(0.0)	1.000

Data are presented as frequency (%). MIS-C: multisystem inflammatory syndrome in children; IVIG: intravenous immunoglobulin; IVMP: intravenous methylprednisolone; ICU: intensive care unit.
Immunomodulators include IVIG, IVMP, and anakinra.